EFFICACY OF PHYTOSOMAL CURCUMIN AMONG PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL

Background and Aim: Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease. No evidence-based drugs or guidelines for NAFLD treatment have been invented to date. However, herbal medicine might reduce hepatocyte fat accumulation. In this article, we aimed to identify the effect of curcumin on NAFLD improvement.Methods: Forty-four patients with NAFLD, aged 20–65 years, were divided into two groups in this randomized, double-blind, and controlled clinical trial. Patients in the curcumin group received 250 mg/day of phytosomal curcumin, while those in the control group received 250 mg/day of placebo for eight weeks. Anthropometric measurements and fasting blood samples were taken at the baseline and at the end of the study. Twenty-four-hour dietary recalls were collected every two weeks throughout the period of study.Results: Analysis was performed on 37 patients (intervention group N = 19, placebo group N = 18). According to our between groups analysis, curcumin significantly reduced (carboxymethyl) lisine (CML). The within-group comparison revealed that weight, waist circumference, hip circumference, waist/ hip, and fat free mass decreased significantly in the curcumin group. However, the result of the between groups comparison indicated no significant changes in the anthropometric variables. Liver enzymes, 8-hydroxy-2 -deoxyguanosine (8-OHdG), and soluble receptors for advanced glycation end products (sRAGE) did not significantly change by the end of the study.Conclusion: Our study indicated that curcumin might be able to reduce advanced glycation end products among NAFLD patients. For confirming these results, we need more studies with longer intervention duration, higher dose of phytosomal curcumin, and larger sample size.

کلیدواژه ها:

Curcumin ، non-alcoholic fatty liver ، advanced glycation end-products ، DNA damage